Hookipa Pharma Inc (HOOK) Stock Price, Quote & News

Company Profile

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of...

Industry: Biotechnology

Sector: Healthcare

Phone: 431 890 6360

Website: www.hookipapharma.com

Address:

350 Fifth Avenue, 72nd Floor Suite 7240, New York, United States

koditrump Feb. 10 at 10:43 PM

$LYFT $HOOK $SCHW

0 · Reply

biovaluable Feb. 9 at 2:29 AM

$BCAB $BCAB $HOOK oh my god such a fuxx company!

0 · Reply

joe77w Feb. 7 at 6:41 PM

$HOOK https://www.otcmarkets.com/filing/html?id=18596713&guid=Aqt-keox_0xjJth

0 · Reply

joe77w Feb. 7 at 6:41 PM

$HOOK https://www.otcmarkets.com/file/company/financial-report/507979/content 30 mln in net equity as of September 30 with 12.2 mln shares would be worth 2.45 USD per share in book value. Then we should Add 7.4 mln USD net by GILEAD for assets purchase plus recents asset sale to Neotrail for undisclosed amount. I assume Dissolution and liquidation costs plus some cash burn should be around 12 mln USD with 25 mln USD left to be liquidated to shareholders when and If certificate of Dissolution filed to Delaware SOS... 25 mln /12.2 shares gives me more than 2 USD per share but according most recent meeting to vote Dissolution liquidation value beetwen 1.28 and 1.72 USD per share, what Is wrong? I would assume 1.72 at least if not more... What if bod decides not to file for Dissolution but seeking a merger , there Is a small chance Dissolution cancelled and operations to resume. I find stock very cheap, a Shell with cash and equity without debt or positive equity around 25/30 mln

0 · Reply

dinnerwithme Feb. 6 at 4:47 AM

$BCAB $BCAB The company's strategy for maintaining its listing has never been successful. Fact check! 1. Maintain MVLS -> Failure (Nasdaq Disapproval) 2. BP partnership -> Failure (only inversagen AI deal) 3. bid compliance -> Failure (until 2/2) 4. PPA induces high stock conversion(11/26) -> failure, Yorkville maybe exit at Dec, Jan. 5. Issuance of Super Voting Rights -> Failure (Nasdaq Disapproval) 6. RS Strategy -> Failed twice 7. cash -> burning state 8. equity -> Only numbers are resolved through a joint venture from a company related to the representative(invergagen AI). deposit is unknown or secured) 9. Reverse merger -> ???? maybe f..... All that remains is liquidation or delisting. However, after liquidation, the cost for liquidation of creditors and executives and employees comes first. There is no shareholder's share. like $HOOK

0 · Reply

joe77w Feb. 6 at 2:39 AM

$HOOK I would expect liquidation to happen at higher range around 1,71 USD given co.completed asset sale to GILEAD and now NEOTRAIL, its a matter of patience. I dont see any downside but only upside, strange pps does not hit 1,28 USD the minimum liquidation value. Holding tight my shares. Do your due diligence before investing your Money. This Is not a financial advice.

0 · Reply

joe77w Feb. 6 at 2:34 AM

$HOOK new asset sale https://www.nasdaq.com/articles/hookipa-pharma-t0-sell-oncology-assets-hb-200-and-hb-700-neotrail-therapeutics

0 · Reply

joe77w Feb. 6 at 12:11 AM

$HOOK new asset sale just happened, bullish view about liquidation value, 1,65 the minimum Just my opinion.

0 · Reply

pointnopoint Feb. 5 at 10:17 PM

$HOOK Does this still hold up?

0 · Reply

biovaluable Feb. 4 at 12:44 PM

$BCAB will move like $HOOK which delisted last year.

0 · Reply

HOOKIPA Pharma T0 Sell Oncology Assets HB-200 And HB-700 To NeoTrail Therapeutics

2026-02-03T14:26:31.000Z - 20 days ago

HOOKIPA Pharma to sell oncology assets to NeoTrail Therapeutics

2026-02-03T14:04:17.000Z - 20 days ago

HOOKIPA Pharma (HOOK) Divests Key Immuno-Oncology Assets

Tue, 03 Feb 2026 08:30:00 -0500 - 21 days ago

HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics

2025-10-31T13:28:07.000Z - 4 months ago

Gilead Sciences (GILD) Acquires Key Assets from HOOKIPA Pharma

Fri, 31 Oct 2025 08:00:00 -0400 - 4 months ago

HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead

2025-07-18T20:21:23.000Z - 7 months ago

HOOKIPA Pharma to delist from Nasdaq and liquidate following Gilead asset sale

Fri, 18 Jul 2025 16:05:00 -0400 - 7 months ago

HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock

Thu, 20 Feb 2025 15:06:00 -0500 - 1 year ago

HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)

Fri, 10 Jan 2025 02:00:00 -0500 - 1 year ago

Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA

Wed, 08 Jan 2025 11:23:00 -0500 - 1 year ago

HOOKIPA Pharma Inc - FORM 8 (OPD)

Tue, 07 Jan 2025 16:05:00 -0500 - 1 year ago

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

Mon, 06 Jan 2025 02:00:00 -0500 - 1 year ago

HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment

Thu, 02 Jan 2025 02:00:00 -0500 - 1 year ago

Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.

Mon, 11 Nov 2024 16:05:00 -0500 - 1 year ago

HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker

Thu, 31 Oct 2024 09:17:00 -0400 - 1 year ago

HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024

Wed, 30 Oct 2024 07:30:00 -0400 - 1 year ago

HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

Tue, 24 Sep 2024 07:30:00 -0400 - 1 year ago

HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

Tue, 17 Sep 2024 08:00:00 -0400 - 1 year ago

Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm

Fri, 30 Aug 2024 08:00:00 -0400 - 1 year ago

HOOKIPA Pharma Announces Board of Directors Changes

Wed, 28 Aug 2024 08:57:00 -0400 - 1 year ago

HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Thu, 08 Aug 2024 16:30:00 -0400 - 1 year ago

HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Mon, 22 Jul 2024 08:30:00 -0400 - 1 year ago

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

Mon, 08 Jul 2024 07:01:00 -0400 - 1 year ago

HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split

Mon, 01 Jul 2024 16:31:00 -0400 - 1 year ago

HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV

Tue, 04 Jun 2024 13:00:00 -0400 - 1 year ago

HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

Thu, 30 May 2024 16:30:00 -0400 - 1 year ago

HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting

Thu, 23 May 2024 17:01:00 -0400 - 1 year ago

HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting

Thu, 09 May 2024 07:01:00 -0400 - 1 year ago

HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

Thu, 25 Apr 2024 07:01:00 -0400 - 1 year ago

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

Wed, 24 Apr 2024 07:01:00 -0400 - 1 year ago

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers

Mon, 22 Apr 2024 14:20:23 -0400 - 2 years ago

Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts

Tue, 16 Apr 2024 16:30:00 -0400 - 2 years ago

HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Wed, 10 Apr 2024 07:01:00 -0400 - 2 years ago

HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration

Fri, 22 Mar 2024 07:01:00 -0400 - 2 years ago

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Wed, 06 Mar 2024 07:01:00 -0500 - 2 years ago

HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference

Mon, 29 Jan 2024 08:01:00 -0500 - 2 years ago

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

Tue, 16 Jan 2024 07:01:00 -0500 - 2 years ago

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

Thu, 21 Dec 2023 07:01:00 -0500 - 2 years ago

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences

Mon, 20 Nov 2023 07:01:00 -0500 - 2 years ago

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Thu, 09 Nov 2023 07:01:00 -0500 - 2 years ago

HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Fri, 03 Nov 2023 12:01:00 -0400 - 2 years ago

HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023

Thu, 02 Nov 2023 16:01:00 -0400 - 2 years ago

HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023

Sun, 22 Oct 2023 06:01:00 -0400 - 2 years ago

HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

Wed, 18 Oct 2023 07:01:00 -0400 - 2 years ago

HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences

Wed, 13 Sep 2023 08:45:00 -0400 - 2 years ago

HOOKIPA Announces Executive Leadership Change

Tue, 12 Sep 2023 07:01:00 -0400 - 2 years ago

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Wed, 06 Sep 2023 07:01:00 -0400 - 2 years ago

HOOKIPA Pharma to participate in upcoming investor conferences in September

Thu, 10 Aug 2023 07:01:00 -0400 - 2 years ago

HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Thu, 03 Aug 2023 07:01:00 -0400 - 2 years ago

HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023

koditrump Feb. 10 at 10:43 PM

$LYFT $HOOK $SCHW

0 · Reply

biovaluable Feb. 9 at 2:29 AM

$BCAB $BCAB $HOOK oh my god such a fuxx company!

0 · Reply

joe77w Feb. 7 at 6:41 PM

$HOOK https://www.otcmarkets.com/filing/html?id=18596713&guid=Aqt-keox_0xjJth

0 · Reply

joe77w Feb. 7 at 6:41 PM

0 · Reply

dinnerwithme Feb. 6 at 4:47 AM

0 · Reply

joe77w Feb. 6 at 2:39 AM

0 · Reply

joe77w Feb. 6 at 2:34 AM

$HOOK new asset sale https://www.nasdaq.com/articles/hookipa-pharma-t0-sell-oncology-assets-hb-200-and-hb-700-neotrail-therapeutics

0 · Reply

joe77w Feb. 6 at 12:11 AM

$HOOK new asset sale just happened, bullish view about liquidation value, 1,65 the minimum Just my opinion.

0 · Reply

pointnopoint Feb. 5 at 10:17 PM

$HOOK Does this still hold up?

0 · Reply

biovaluable Feb. 4 at 12:44 PM

$BCAB will move like $HOOK which delisted last year.

0 · Reply

Stock_Catcher Feb. 3 at 1:32 PM

$HOOK HOOK HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics

0 · Reply

contrarianinme Feb. 3 at 10:00 AM

$HOOK what is happening with this stock

0 · Reply

Popeye989 Oct. 14 at 3:16 PM

$HOOK another one bites the dust. So long from the watch list

0 · Reply

WatchTheseTickers Oct. 7 at 1:37 AM

If PRHI can crack above key resistance, it may go vertical. The fundamentals are aligned with technicals: micro float, oversold zone, and huge upside range. Add a short squeeze into the mix and you’ve got a textbook 20–50× candidate. $IBG $MODD $AVTX $YOSH $HOOK

0 · Reply

WallStJoey Oct. 3 at 1:06 PM

If GIPR becomes the next REIT-crypto hybrid play, the re rate will be violent. Add in a micro float, real tenants, and a book value that’s completely ignored this could be the next legendary rerate ticker. Eyes on this before it headlines. $MNPR $THMO $LGVN $HOOK $PEV

0 · Reply

DataCenterTrader Sep. 26 at 11:25 PM

IVDA is a rare find: ✔️ Robotics ✔️ AI ✔️ Drones ✔️ Undervalued ✔️ At the exact bottom This isn’t just a low float trade this is a tech sleeper with real-world potential. One volume spike or news cycle, and it could go vertical. $NAOV $COSM $HOOK $AVTX $SNMP

0 · Reply

WallStJoey Sep. 7 at 8:34 PM

SKYQ is a deep sleeper with massive upside. 📈 Real revenue 🔋 Clean tech infrastructure 🧠 Blockchain expansion 🪙 Energy tokenization deal inked 💥 No dilution, low cap, and the chart is coiled This could wake up violently. $BFRG $HOOK $STSS $NAOV

0 · Reply

elmono Sep. 6 at 9:16 PM

$HOOK always right

0 · Reply

joe77w Aug. 26 at 7:40 PM

$HOOK Just because co. Was so plenty of cash and with very little liabilities, my humble opinion liquidation will happen at High end therefore around 1.6/1.7 USD Stock below only because on OTC, smart and professional investors with no restriction buying a lot

0 · Reply

joe77w Aug. 26 at 6:43 PM

$HOOK 15/21 mln available for DISTRIBUTION according sec filing or 1.28/1.72 USD, clearly stated, still trading at huge discount vs minimal liquidation estimated value https://www.otcmarkets.com/filing/html?id=18596713&guid=SBE-kW3a1BQFJth

0 · Reply

joe77w Aug. 26 at 6:35 PM

$HOOK huge volume today, stock hit 1.07 because Min liquidation value set at 1.28 while the max 1.72 USD per share. Co was plenty of cash before selling assets to Gilead for 10 mln USD so I bet liquidation value likely around 1.6/1.7 given the almost no liabilities and significant cash resources. It Is clearly written in sec filings, liquidation range 1.28/1.72, I dont see reason trading below the low end

0 · Reply

WAYWARD_SUN Aug. 14 at 7:00 PM

$TRIB $TRIL $HOOK 😘

0 · Reply

Market Cap	10.24M
Revenue (ttm)	43.95M
Net Income (ttm)	-43.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-98.98%
Debt to Equity Ratio	0.00

Volume	147,700
Avg Vol	112,680
Day's Range	N/A - N/A
Shares Out	12.19M
Stochastic %K	50%
Beta	0.93
Analysts	Hold
Price Target	$2.00